Clinical trials: Overweight, Obesity
Change in Total Body Fat Mass Percentage Loss Versus Body Weight
Evaluation of Sinetrol® Xpur in Fat Mass Reduction on Overweight and Obese Subjects
This study aims to evaluate effects of a 16-week supplementation with a polyphenol rich extract, Sinetrol® Xpur, on fat mass accumulation and body weight management improvement.Subjects were overweight or obese and received…
- Trial name
- NCT04149158
- Testing
- Sinetrol® Xpur
- Where
- Spain
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Fytexia
Overweight and Obesity, Healthy
the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, and pharmacokinetics of the Mulberry Twig Alkaloids tablets (WH006) in healthy ，overweight and obesity subjects.
- Trial name
- NCT06490263
- Testing
- Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd
Obesity
An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
The goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are: Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple…
- Trial name
- NCT06891287
- Testing
- RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- RANI Therapeutics
Obesity
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid…
- Trial name
- NCT07247084
- Testing
- Tirzepatide, Standard of Care
- Where
- 30 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Overweight/Obesity
A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study. All trial participants are required to use TQF3250 capsules or placebo.
- Trial name
- NCT07798284
- Testing
- TQF3250 capsules
- Where
- 10 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sarcopenia, Obesity and Obesity-related Medical Conditions
INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY
The expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other IMM01-STEM clinical trial in their physician's opinion for…
- Trial name
- STEM-META-EAP (NCT06784297)
- Testing
- IMM01-STEM
- Sponsor
- Immunis, Inc.
Overweight, Obesity
Efficacy and Safety of Glucosanol in Maintaining Body Weight
To date, there is no clinical evidence on the efficacy and safety of Glucosanol in maintaining weight loss beyond the study duration of 12 weeks.
- Trial name
- NCT01435278
- Testing
- Glucosanol
- Where
- Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Cardiovascular Diseases
Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
A retrospective review of body composition changes in patients who participate in a 9-week non-invasive intensive health care provider supervised weight loss program as an overall cohort and in sub-cohorts of interest.
- Conditions
- Obesity, Cardiovascular Diseases, Metabolic Syndrome, Metabolic Disease
- Trial name
- NCT05219240
- Testing
- 20Lighter Program
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- 20Lighter
Obesity
Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
The study is designed to assess whether repeated dosing with CE-326,597 will cause patients with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become symptomatic.
- Trial name
- NCT00576589
- Testing
- CE-326,597
- Where
- 12 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Safety and Tolerability
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2…
- Trial name
- NCT06000891
- Testing
- ZP7570
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Chronic Weight Management
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
APD356-A001-402 is a multicenter, double-blind, randomized, parallel-group pilot study of 12-week duration in overweight and obese adults.
- Trial name
- NCT01987427
- Testing
- lorcaserin + phentermine-HCl
- Where
- 13 sites in United States
- Volunteers
- 344 people
- Sponsor
- Eisai Inc.
Obesity
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800…
- Trial name
- NCT00748605
- Testing
- S-2367 1600 mg q.d. 54 Weeks, S-2367 1600 mg q.d. 60 weeks, LCD (low calorie diet)
- Where
- 40 sites in United States
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days.
- Trial name
- NCT04447261
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Healthy Overweight Obese
Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters
The purpose of this study is to determine the safety and tolerability of Gelesis200.
- Trial name
- STAGE (NCT02652962)
- Testing
- Gelesis200
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gelesis, Inc.
Overweight, Obese
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
The purpose of this study is to evaluate the multiple dose safety and tolerability of RM-493 (setmelanotide) as well as pharmacokinetic (PK) and pharmacodynamic (PD; weight loss) profile, in healthy obese patients for 2 to 4…
- Trial name
- NCT02431442
- Testing
- RM-493
- Volunteers
- 57 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected)…
- Trial name
- NCT07225816
- Testing
- Liraglutide, Oral Semaglutide, Semaglutide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals
The purpose of this study is to determine whether low level laser light therapy is effective in reducing circumference of the waist, hips and upper abdomen in obese individuals.
- Trial name
- NCT01821352
- Testing
- Erchonia Obesity Laser
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Depression
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
- Trial name
- NCT00624858
- Testing
- naltrexone SR 32 mg/ bupropion SR 360 mg daily
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Orexigen Therapeutics, Inc
Overweight or Obesity
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
- Trial name
- NCT06830343
- Testing
- SYH9017, Wegovy ®
- Where
- China
- Volunteers
- 66 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Diabetes, Obesity
Prospective Metabolic Surgery in T2DM Chinese Subjects
The primary goal of this study is to assess impact of metabolic surgery on glycemic control in diabetic patients.
- Trial name
- NCT02217943
- Testing
- Roux-en-Y gastric bypass, Sleeve gastrectomy
- Where
- 6 sites in China
- Volunteers
- 101 people
- Sponsor
- Ethicon Endo-Surgery
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.